April 18, 2024

Respiratory Disease Vaccine Market Size To Gain USD 116.53 Bn by 2032

The respiratory disease vaccine market size is poised to grow by USD 116.53 billion by 2032 from USD 95.13  billion in 2022, exhibiting a CAGR of 2.05% during the forecast period 2023-2032. 

Respiratory Disease Vaccine Market Size 2023 To 2032

Key Takeaways

  • Asia Pacific dominated the market in 2022 with the largest market share of 55% in 2022.
  • By Distribution Channel, the hospital segment dominated the market with the highest market of 55% in 2022.
  • By Disease Type, the chronic obstructive pulmonary disease (COPD) segment dominated the market in 2022.
  • By Type, the viral vaccine segment contributed more than 55% of revenue share in 2022.
  •  By Type, the bacterial vaccine segment is expected to expand at a significant CAGR during the forecast period.
  • By Age Group, the adult segment dominated the market with a major market share of 77% in 2022.
  • By Age Group, the pediatric segment is expected to be the most lucrative segment of the market throughout the forecast period.
  • By Infection, the COVID-19 segment captured more than 70% of market share in 2022.
  • By Infection, the Respiratory Syncytial Virus (RSV) segment is expected to grow at a significant rate during the forecast period.

Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Respiratory disease vaccine market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.

To begin with, the Respiratory disease vaccine Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.

Get a Sample Reporthttps://www.precedenceresearch.com/sample/3249

Report Scope of the Respiratory Disease Vaccine Market:

Report Coverage Details
Market Size in 2023 USD 97.08 Billion
Market Size by 2032 USD 116.53 Billion
Growth Rate from 2023 to 2032 CAGR of 2.05%
Largest Market Asia Pacific
Base Year 2022
Forecast Period 2023 To 2032
Segments Covered By Disease Type, By Type, By Age Group, and By Infection, By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Chip Resistor Market Size To Rake USD 3.7 Bn By 2032

The empirical study on the global Respiratory disease vaccine market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Respiratory disease vaccine Market. Our market report for the Respiratory disease vaccine market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.

Top Key Players:

  • Sanofi
  • GSK plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bavarian Nordic
  • EMERGENT
  • CSL Limited
  • Moderna, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech

Segments Covered in the Report:

Data Sources and Methodology

To gather comprehensive insights on the Global Respiratory disease vaccine Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.

We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Respiratory disease vaccine Market.

The most resonating, simple, genuine, and important causes because of which you must decide to buy the Respiratory disease vaccine market report exclusively from precedence research

  • The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.

Key Features of the Report:

  • Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
  • Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
  • Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.

Market Segmentation:

By Disease Type

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pertussis
  • Pneumonia
  • Measles
  • Diphtheria

By Type

  • Viral Vaccine
  • Bacterial Vaccine
  • Combination Vaccine

By Age Group

  • Pediatric
  • Adult

By Infection

  • COVID-19
  • Influenza
  • Respiratory Syncytial Virus (RSV)
  • Pneumonia
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Reasons to Consider Purchasing the Report:

  • Enhance your market research capabilities by accessing this comprehensive and precise report on the global Respiratory disease vaccine market.
  • Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
  • Benefit from in-depth research and analysis of the latest trends shaping the global Respiratory disease vaccine market.
  • Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Respiratory disease vaccine market.
  • Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
  • Discover not only the cutting-edge technological advancements in the global Respiratory disease vaccine market but also the strategic plans of industry leaders.

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Respiratory Disease Vaccine Market 

5.1. COVID-19 Landscape: Respiratory Disease Vaccine Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Respiratory Disease Vaccine Market, By Disease Type

8.1. Respiratory Disease Vaccine Market Revenue and Volume, by Disease Type, 2023-2032

8.1.1. Chronic Obstructive Pulmonary Disease (COPD)

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Pertussis

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Pneumonia

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Measles

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. Diphtheria

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Respiratory Disease Vaccine Market, By Type

9.1. Respiratory Disease Vaccine Market Revenue and Volume, by Type, 2023-2032

9.1.1. Viral Vaccine

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Bacterial Vaccine

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Combination Vaccine

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Respiratory Disease Vaccine Market, By Age Group 

10.1. Respiratory Disease Vaccine Market Revenue and Volume, by Age Group, 2023-2032

10.1.1. Pediatric

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Adult

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Respiratory Disease Vaccine Market, By Infection

11.1. Respiratory Disease Vaccine Market Revenue and Volume, by Infection, 2023-2032

11.1.1. COVID-19

11.1.1.1. Market Revenue and Volume Forecast (2020-2032)

11.1.2. Influenza

11.1.2.1. Market Revenue and Volume Forecast (2020-2032)

11.1.3. Respiratory Syncytial Virus (RSV)

11.1.3.1. Market Revenue and Volume Forecast (2020-2032)

11.1.4. Pneumonia

11.1.4.1. Market Revenue and Volume Forecast (2020-2032)

11.1.5. Others

11.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 12. Global Respiratory Disease Vaccine Market, By Distribution Channel

12.1. Respiratory Disease Vaccine Market Revenue and Volume, by Distribution Channel, 2023-2032

12.1.1. Hospital & Retail Pharmacies

12.1.1.1. Market Revenue and Volume Forecast (2020-2032)

12.1.2. Government Suppliers

12.1.2.1. Market Revenue and Volume Forecast (2020-2032)

12.1.3. Others

12.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 13. Global Respiratory Disease Vaccine Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.1.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.1.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.1.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.1.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.1.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.1.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.1.7.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.1.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.1.7.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.2.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.2.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.2.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.2.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.2.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.2.7. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.2.9.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.2.9.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.2.10. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.2.12.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.2.12.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.2.12.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.2.14.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.2.14.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.2.14.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.3.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.3.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.3.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.3.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.3.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.3.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.3.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.3.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.3.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.3.10.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.3.10.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.3.10.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.3.11.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.3.11.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.3.11.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.4.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.4.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.4.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.4.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.4.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.4.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.4.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.4.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.4.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.4.10.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.4.10.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.4.10.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.4.11.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.4.11.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.4.11.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.5.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.5.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.5.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.5.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.5.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)

13.5.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)

13.5.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

13.5.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

Chapter 14. Company Profiles

14.1. Sanofi

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. GSK plc

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Merck & Co., Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Pfizer Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bavarian Nordic

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. EMERGENT

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. CSL Limited

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Moderna, Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Serum Institute of India Pvt. Ltd.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Sinovac Biotech

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

 

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

Precedence Statistics – Empowering Your Data Insights

 

Contact Us

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *